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ABSTRACT 
Fungal cholangitis is a potentially life-threatening condition. As amphotericin B (AMB) has a 
broad antimycotic spectrum, its biliary penetration and activity was determined in two 
patients treated with liposomal AMB (LAMB) and in one patient on AMB colloidal 
dispersion (ABCD). Biliary and plasma AMB were quantified by high-pressure-liquid-
chromatography after purification by solid phase extraction. For assessment of biliary AMB 
activity, isolates of Candida (C.) albicans, C. tropicalis, C. glabrata and C. krusei were 
incubated in porcine bile at AMB concentrations of 0.025 - 5.00 mg/L. Additionally, patient 
bile samples retrieved for AMB quantification were inoculated with the same Candida strains. 
Biliary AMB concentrations were lower and displayed a slower rise and decline than plasma 
levels. The highest penetration ratio as expressed by the ratio between the area under the time-
AMB-concentration curve in bile and plasma (liberated AMB) over the sampling period 
(AUC0-n bile/AUC0-n LI plasma) amounted to 0.28. Proliferation of C. albicans and C. tropicalis in 
bile was similar to that in culture medium whereas growth of C. glabrata was diminished and 
proliferation of C. krusei was absent in bile. In comparison with medium, AMB activity 
decreased in spiked porcine bile. In all but one patient bile sample, fungal growth was delayed 
or lacking, even when AMB was not detectable. However, no fungicidal effect was observed 
in patient bile at AMB concentrations of up to 1.28 mg/L. Thus, a reliable response of fungal 
cholangitis to treatment with LAMB or ABCD cannot be anticipated.  
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1. Introduction 
Fungal cholangitis is a life-threatening condition affecting mainly immune-compromised 
persons, patients with choledocholithiasis, cancer, bile duct strictures, primary sclerosing 
cholangitis or liver transplant recipients [1-3]. Liver abscess, severe sepsis and septic shock 
are frequent complications. Data on biliary concentrations of antifungals are scarce. Because 
of its broad fungicidal activity, amphotericin B (AMB) is still a cornerstone in the treatment 
of invasive fungal infections (IFIs). AMB has a high protein binding exceeding 90 percent. 
After administration of its conventional deoxycholate formulation, it is eliminated via urine 
and bile. As AMB deoxycholate displays a considerable infusion-related and renal toxicity, 
less toxic lipid formulations such as liposomal AMB (LAMB) or AMB colloidal dispersion 
(ABCD) are preferred in intensive care medicine. Therefore, we assessed biliary and plasma 
AMB levels during treatment with LAMB or ABCD in critically ill patients.  
 
2. Patients and methods 
2.1. Pharmacokinetic analysis 
Adult critically ill patients on treatment with lipid-formulated AMB for proven or suspected 
IFI and an indication for retrieval of bile were enrolled. LAMB (AmBisome®, Gilead, Foster 
City, CA, USA) and ABCD (Amphocil®, Chiesi Pharmaceuticals, Vienna, Austria) were 
infused at standard doses (~ 3-5 mg/kg once daily) over four hours for suspected or proven 
IFI. The first ABCD dose amounted to 50 percent of the maintenance dose in order to avoid 
infusion-related toxicity. The bile collection bags were changed before AMB infusion as well 
as 4, 6, 10, 16 and 24 hours after start of infusion. Heparinised 2-mL blood samples were 
drawn whenever the collection bag was changed. Bile and blood sampling was performed on 
day 1 of therapy with lipid-formulated AMB and at approximately steady state (day 4 in 
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Patient 3, day 5 in patient 2 and day 7 in Patient 1). Blood samples were centrifuged 
immediately. Bile and plasma were stored at  
-80 °C. In plasma, lipid-bound AMB and AMB that had been liberated from lipid-
encapsulation were separately quantified as described previously [4]. For bile samples, the 
method had to be modified because of high viscosity of bile and suboptimal signal noise ratio. 
Bile was filtrated (Filtropur S 0.2 µm pore size; Sarstedt, Nümbrecht, Germany). 
Subsequently, 500 µL of filtered bile was treated with 1 mL of dimethyl sulfoxide (Merck, 
Darmstadt, Germany) and methanol (Rotisolv®, Carl Roth, Karlsruhe, Germany; 1:1, v/v). For 
high performance liquid chromatography, a Zorbax 300SB-C18 column (Agilent 
Technologies, Vienna, Austria) was used. The mobile phase consisted of acetonitrile 
(Rotisolv®, Carl Roth, Karlsruhe, Germany) and 10 mM NaH2PO4 (Merck, Darmstadt, 
Germany; 45:55, v/v). Inter and intra-day variability for biliary total AMB levels were < 15 
percent, the lower limit of quantification (LLOQ) < 0.01 mg/L. Liberated and lipid-bound 
AMB could be separated in one bile specimen obtained by endoscopy (data not shown). In all 
bile samples taken from Patient 1-3, only total AMB could be measured. However, we assume 
that total biliary AMB comprises exclusively liberated AMB since no lipid-bound AMB 
penetrates into bile. Therefore, “biliary AMB” means total biliary AMB which consists of 
liberated AMB (see 4. Discussion). Based on this assumption, the penetration ratio for AMB 
into bile was defined as the ratio between the area under the time-total-AMB-concentration 
curve in bile and the area under the time-liberated-AMB-concentration curve in plasma over 
the sampling period (AUC0-n bile/AUC0-n LI plasma) [5]. Total AMB plasma levels were obtained 
by addition of plasma concentrations of liberated and lipid-bound AMB. Pharmacokinetics 
were calculated by a non-compartmental model using Kinetica-2000® (InnaPhase 
Corporation, Champs-sur-Marne, France). The area under the concentration-time curve over 
the sampling period (AUC0-n) was computed using the log linear method, whenever the 
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concentration in a trapezoid decreased, or with the trapezoidal method when the concentration 
increased. 
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2.2. Microbiological diagnostics 
Candida (C.) krusei and C. glabrata were cultured from bile of Patient 3. Minimum inhibitory 
concentration (MIC) values were determined for isolates obtained from Patient 3.  
Susceptibility testing was performed by the agar based ETest method (AB Biodisk, Solna, 
Sweden) using RPMI-2G agar plates (Sigma, Vienna, Austria). According to the 
manufacturer's recommendations (Etest technical guide number 4. Antifungal susceptibility of 
yeasts, AB Biodisk, Solna, Sweden) plates were inoculated by dipping a sterile swab into the 
inoculum suspension adjusted to the turbidity of a 0.5 McFarland standard and streaked across 
the agar surface in three directions. Agar plates were dried for at least 15 minutes before 
applying the ETest strips. AMB MICs were determined after 24 to 48 h of incubation at 37 °C 
as the lowest drug concentration inhibiting any visible growth (100 percent).  
 
2.3. In-vitro and ex-vivo simulations 
Candida isolates (C. albicans, C. tropicalis, C. glabrata and C. krusei), all deep-frozen for 
storage, were grown on Sabouraud glucose (SAB) agar plates for 24 h at 36 ± 1 °C. Patient 
bile samples and porcine bile were filtered in order to abolish any bacterial or fungal 
contamination (Filtropur S 0.45 µm and 0.2 µm pore size, Sarstedt, Nümbrecht, Germany). 
Subsequently, samples were inoculated with 1 x 104 Candida cells. Controls were performed 
in culture medium (RPMI 1640 medium, Sigma-Aldrich, Austria) at pH 7.2 and in RPMI 
adjusted to biliary pH which was 7.8 with NaOH. Fungal suspensions (40 µl) were added to 
patient bile samples, porcine bile, RPMI at pH 7.2 and RPMI at pH 7.8 (sample volume 3 ml). 
Tubes were gently shaken for 48 h at 36 ± 1 °C. After 7, 12, 24 and 48 hours, respectively, 
aliquots of 100 µl were drawn and diluted 10-fold or 100-fold in double-distilled water. 
Aliquots (50 µl) of these dilutions were plated in duplicate on SAB agar plates with an 
automatic spiral plater (model WASP 2, Don Whitley Scientific, Shipley, United Kingdom). 
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The plates were incubated at 37 ± 1 °C for 24 h and the numbers of fungal CFU were counted 
and assessed, considering the duplicity and the dilution [6].  
Fungal growth in bile and effects of bile on AMB pharmacodynamics were investigated in-
vitro. Filtered porcine bile was spiked with 0.0 (control), 0.025, 0.05, 0.5, 1.0 and 5.0 mg/L of 
AMB deoxycholate (conventional AMB) and inoculated with C. albicans, C. tropicalis, C. 
glabrata and C. krusei (104 conidia per inoculum).  
For assessment of antifungal activity of AMB in patient bile samples ex-vivo simulation was 
performed. Patient bile samples retrieved for AMB quantification were filtered and inoculated 
with the same Candida strains (104 conidia per inoculum). For comparison, filtered porcine 
bile and medium at pH 7.2 and pH 7.8 were spiked with AMB deoxycholate at concentrations 
measured in patient bile samples. 
 
3. Results 
3.1. Patients 
Three patients were enrolled (see Table 1). Patient 1 and Patient 2 had recently undergone 
orthotopic liver transplantation and bile sampling was performed via T-tubes which had been 
inserted at the operation. Patient 3 was also a liver transplant recipient and presented with 
liver abscesses due to strictures of his bile duct anastomosis. Therefore, bile was deviated via 
bile duct drainage. C. krusei and C. glabrata were cultivated from bile of Patient 3. MIC 
values are displayed in Table 1.  
 
3.2. Biliary and plasma pharmacokinetics of amphotericin B 
As displayed in Figure 1, biliary AMB concentrations were lower than the simultaneous 
plasma levels of total, lipid-bound and liberated AMB. The rise of AMB concentrations in 
bile and their decline were delayed in comparison with plasma. Patient 1 presented the highest 
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biliary AMB concentrations (maximum biliary AMB 1.28 mg/L) on day 7 of LAMB therapy. 
Whereas AMB was already detectable in bile collected after the first LAMB infusion (Patient 
1), no AMB could be recovered from bile within 24 hours after a single 200-mg dose of 
ABCD (Patient 3). In Patient 1, penetration ratios amounted to 0.15 and 0.28 after single and 
multiple doses, respectively. In Patient 2 and Patient 3 penetration ratios were 0.12 and 0.05, 
respectively, after multiple doses. Plasma pharmacokinetics of liberated, lipid-bound, and 
total AMB during treatment with LAMB (Patient 1 and Patient 2) or ABCD (Patient 3) are 
summarized in Table 2.  
 
3.3. Biliary amphotericin B pharmacodynamics assessed by in-vitro simulations 
Growth of C. albicans and C. tropicalis in native porcine bile (pH 7.8) was comparable to that 
in RPMI medium at pH 7.2 and at pH 7.8. The antifungal effect of AMB, however, was 
different in porcine bile and in medium. In medium containing AMB at a concentration of 5 
mg/L, C. albicans and C. tropicalis were eradicated after an exposure of 7 to 24 hours. At a 
concentration of 1 mg/L, the number of CFUs of C. albicans remained almost constant over a 
24 h-incubation period but CFU count of C. tropicalis slightly declined. In bile, however, an 
AMB concentration of 5 mg/L stopped proliferation, but did not result in a reduction of CFU 
of C. albicans or C. tropicalis. Lower concentrations were completely ineffective. 
By contrast, proliferation of C. glabrata in porcine bile was lower than in medium and was 
inhibited by biliary AMB concentrations at 1 mg/L and 5 mg/L. Unlike in bile, in culture 
medium, C. glabrata was eradicated by 1 mg/L and 5 mg/L of AMB at pH 7.8 and by 5 mg/L 
of AMB at pH 7.2. C. krusei did not display any proliferation in porcine bile and CFU 
remained unchanged over a 48 h-incubation in native and in AMB-spiked porcine bile. Thus, 
in bile, none of the tested strains was killed even when exposed to an AMB-concentration of  
5 mg/L (Table 3). 
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3.4. Biliary amphotericin B pharmacodynamics assessed by ex-vivo simulations 
Data obtained from ex-vivo simulations are summarized in Table 4. In bile samples obtained 
from Patient 1 treated with LAMB, CFU of C. tropicalis and C. albicans remained constant. 
AMB at concentrations of up to 1.28 mg/L had no fungicidal effect. A slow and inconstant 
growth of C. albicans was observed in bile samples of Patient 2 (also on LAMB) at AMB 
concentrations of 0.40 mg/L or below. In bile samples of Patient 3 who received ABCD, no 
AMB was detectable after the first dose and AMB concentrations were still very low on day 4 
of treatment. Inoculation with C. krusei or C. glabrata resulted in variable growth that was 
slower than in medium. Thus, AMB concentrations of 0.04 mg/L or below had no obvious 
effect on proliferation of C. krusei and C. glabrata. 
 
4. Discussion 
During treatment with LAMB or ABCD, biliary AMB levels were lower than in plasma. 
AMB plasma pharmacokinetics were comparable with previously reported data [7, 8]. When 
administered as a lipid formulation such as LAMB or ABCD, AMB is slowly released from 
its lipid encapsulation in the plasma. This liberated AMB fraction comprises unbound 
(ultrafiltrable) and protein-bound AMB. As plasma protein binding of AMB amounts to > 90 
percent depending on its concentration most of the liberated AMB is bound to plasma protein. 
In addition, there is a fraction of lipid-bound AMB [9, 10]. In the present study, liberated and 
lipid-bound AMB were separately quantified in the plasma but separation of the unbound and 
the protein-bound fraction has not been performed. Thus, the term “liberated AMB” 
comprises unbound and protein-bound AMB. “Total AMB” comprises liberated and lipid-
bound AMB [4]. Plasma pharmacokinetics of lipid-bound AMB depends on the applied 
formulation. [10]. In bile samples, only total AMB has been determined. Based on 
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measurements in a single bile sample (data not shown) we suppose that biliary AMB consists 
exclusively of liberated AMB. Therefore, we compared biliary AMB concentrations which 
liberated AMB plasma levels. It remains to be clarified to what extent biliary AMB is bound 
to proteins or other biliary components. 
Published data on AMB penetration into bile are limited. In a dog model, biliary AMB 
concentration amounted to 0.75 mg/L one day after administration of AMB deoxycholate. 
Biliary obstruction led to slightly increased AMB serum levels [11]. In studies on isolated 
perfused rat liver, 1-3 percent of administered AMB deoxycholate but only 0.01-0.08 percent 
of LAMB could be recovered from bile within 2 hours [12, 13]. A concentration of 5 mg/L 
exceeding the simultaneous plasma levels was reached by AMB deoxycholate therapy in bile 
of a young patient suffering from Candida cholecystitis [14]. Biliary AMB levels exceeding 
40 mg/L were measured in a cancer patient treated with AMB deoxycholate and subsequently 
with AMB lipid complex (Abelcet®) which is a third clinically used lipid formulation [15]. 
Faecal AMB excretion by healthy volunteers was much lower after infusion of LAMB than 
after AMB deoxycholate (4 vs. 43 percent of the administered dose within a week) [16]. In 
our study cohort, biliary AMB concentrations were lowest in Patient 3 who displayed the 
highest plasma bilirubin level. However, systemic clearance of liberated AMB was only 
slightly delayed in patients with cholestatic liver disease treated with ABCD suggesting a 
limited role of biliary excretion [8]. From different body fluids such as ascites, pleural 
effusion and epithelial lining fluid, only liberated AMB at relatively low concentrations was 
recovered [17-19]. In a single bile sample, we succeeded in separation of lipid-bound from 
liberated AMB but we detected only liberated AMB (data not shown). Thus, only small 
amounts of AMB, probably the liberated component, appear to be excreted via the bile during 
treatment with LAMB or ABCD. By contrast, in liver tissue, AMB concentrations of ~ 100 
µg/g were measured, probably because of accumulation in reticuloendothelial cells [20].  
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For comparison, a biliary fluconazole peak level of 11.6 mg/L was measured after a single 
200 mg-infusion in a patient with a Candida cholecystitis [21]. According to the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) the MIC break point of 
fluconazole susceptibility is ≤ 2 mg/L for C. albicans, C. krusei and C. tropicalis and ≤ 0.002 
mg/L for C. glabrata. Caspofungin reached a biliary concentration of 1.0 mg/L after a 70 mg-
infusion, and micafungin 1.9 mg/L after administration of 150 mg [22, 23]. The EUCAST 
break point for susceptibility is ≤ 0.016 mg/L for C. albicans and ≤ 0.03 mg/L for C. glabrata. 
The two non-albicans Candida strains isolated from bile of Patient 3 displayed MIC values –
as determined by ETest - substantially exceeding the biliary AMB concentrations achieved by 
ABCD treatment. The EUCAST MIC breakpoint of AMB susceptibility is ≤ 1 mg/L for most 
Candida species. AMB MIC values of 0.03 - 4 mg/L have been recently identified for 
Candida isolates with a value of 1 mg/L in numerous isolates, particularly of Candida non-
albicans strains [24-26]. Only in Patient 1, LAMB yielded biliary AMB concentrations 
slightly above 1 mg/L at day 7 of treatment. In the bile samples of Patient 2 and Patient 3, 
AMB concentrations achieved by treatment with LAMB or ABCD were markedly lower. 
High peak levels, however, would be crucial for antifungal efficacy as AMB displays 
concentration-dependent pharmacodynamics [27]. The clinical impact of target-site 
concentrations in relation to MICs determined by E-Test in-vitro is not yet clear. The 
chemical properties of the respective target compartment may influence pharmacodynamics of 
antimicrobial agents. Therefore, we assessed proliferation of typical fungal pathogens in bile 
in-vitro and ex-vivo in order to detect eventual effects of this particular matrix on fungal 
growth as well as on antimycotic activity of AMB. The effect of porcine bile on proliferation 
of Candida turned out to be variable. However, delayed fungal growth, even in the absence of 
AMB, was observed in most of the bile samples, particularly in ex-vivo samples. This 
suggests a potential inhibitory effect of certain biliary components on Candida. A decrease of 
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C. albicans metabolism in presence of bile acids at concentrations of 20-240 mg/L has been 
demonstrated by microcalorimetry. Cholic acid had the strongest effect, followed by 
glycocholic acid and taurocholic acid [28]. Obviously, this effect does not generally protect 
against fungal cholangitis or cholecystitis, particularly in patients at high risk. 
Unlike in culture medium, fungal killing could not be achieved by incubation with AMB, in 
any of our human and porcine bile samples, even at a concentration of 5 mg/L which exceeds 
the biliary AMB levels reached in our study patients. Therefore, an inhibitory effect of bile on 
antifungal activity of AMB has to be considered. Reduced AMB susceptibility of C. albicans 
in the presence of porcine or bovine bile extract (6.25 percent w/v) with an increase in MIC 
(32 mg/L versus 1 mg/L) has been previously reported [29]. Similarly, addition of only 0.8 
percent of bovine bile to culture medium led to a decrease in AMB susceptibility of C. 
glabrata, C. krusei, C. parapsilosis and C. tropicalis. The susceptibility of C. albicans to 
AMB, however, was maintained in presence of 0.8 percent of bile [30].  
Interpretation of our pharmacokinetic data requires consideration of the specific conditions of 
our study cohort comprising only three patients. All patients were liver transplant recipients 
with cholestatic graft dysfunction. Thus, in patients with normal liver function, biliary AMB 
excretion might be markedly higher. Furthermore, subnormal albumin levels may have 
influenced plasma protein binding of liberated AMB. An undefined part of excreted bile was 
collected via T-tube or bile duct drainage. Hence, calculation of the biliary total AMB 
excretion was not feasible. Unlike in plasma, liberated and lipid-bound AMB could be 
separated in one bile sample only. Patient 1 and Patient 3 suffered from acute renal failure 
requiring renal replacement by continuous veno-venous haemofiltration (CVVH). However, 
CVVH has probably no significant influence on pharmacokinetics of the liberated AMB 
fraction during treatment with LAMB or ABCD [7]. In-vitro MICs were determined in three 
isolates from one patient only. Concerning in-vitro simulations, differences in composition of 
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human and porcine bile have to be taken into account. Ex-vivo simulation revealed impaired 
growth of the investigated Candida strains in human bile. This raises questions on their 
pathogenetic role in cholangitis. The small number of arbitrarily selected – albeit clinically 
relevant - Candida strains tested in-vitro and ex-vivo is a limitation of our study. 
In conclusion, biliary total AMB concentrations achieved in critically ill liver transplant 
recipients by treatment with LAMB or ABCD were close to or even markedly below the in-
vitro MIC values of relevant pathogens. Biliary AMB is probably exclusively liberated AMB. 
In addition, the results of in-vitro and ex-vivo simulations suggest an inhibitory effect of bile 
on the antifungal activity of AMB. Based on these findings and given the lack of clinical 
outcome data, the efficacy of LAMB and ABCD for treatment of fungal cholangitis appears to 
be questionable. 
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Figure 1: Amphotericin B (AMB) concentration-time profiles in plasma and in bile during 
treatment with liposomal AMB (LAMB, Panel A and B) and AMB colloidal dispersion 
(ABCD, Panel C and D) 
 
 
Legend to Figure 1 
Amphotericin B (AMB) concentration-time profiles in plasma and in bile during treatment 
with liposomal amphotericin B (LAMB), (Panels (a) and (b)), and amphotericin B colloidal 
dispersion (ABCD), (Panels (c) and (d)); LI, AMB that has been liberated from its lipid-
encapsulation; LB, lipid-bound AMB; TO, total AMB (calculated by addition of liberated and 
lipid-bound AMB). The respective blood samples for measurement of plasma concentrations 
were drawn at the end of each bile collection, whenever the collection bag was changed 
(before as well as 4, 6, 10, 16 and 24 h after start of infusion). In plasma, liberated AMB and 
lipid-bound AMB were separately quantified. In the bile samples, separation was not 
performed and total AMB was determined. Total biliary AMB, however, probably comprises 
exclusively liberated AMB; (1) first isolate of C. krusei; (2) second isolation of C. krusei 36 
days later; C., Candida 
 
1 
 
Table 1: Demographic and clinical characteristics of the patients 
Patient  1 2 3 
Age (years) 60 57 67 
Sex male female male 
Body weight (kg) 90 53 72 
CVVH yes no yes 
    
Laboratory values    
 Creatinine (mg/dL) 0.69 1.51 2.89 
 Bilirubin (mg/dL) 4.23 11.53 20.58 
 aPTT (sec) 41 29 51 
 PT (%)  60 110 54 
 INR 1.3 0.9 1.4 
 AST (U/L) 32 61 63 
 ALT (U/L) 44 134 65 
 γGT (U/L) 104 38 205 
 Alk. phos. (U/L) 327 63 112 
 Albumin (g/dL) n.d. 2.35 2.40 
 COP (mmHg) 23.3 20.7 15.6 
 Total protein (g/dL) 6.5 6.3 4.5 
    
Main diagnoses St. p. LTX (FLC), 
sepsis, pneumonia, 
ICH, cholangitis liver 
abscess 
St. p. LTX  
(M. Wilson) 
St. p. LTX (FLC), 
liver abscess, 
sepsis, pneumonia 
Time from LTX  1 month 3 days 8 months 
AMB indication   probable pulmonary 
aspergillosis 
pre-emptive therapy 
of suspected 
pulmonary 
aspergillosis 
Candida 
cholangitis 
Evidence of IFI microscopic detection 
of Aspergillus in BAL 
halo sign at CT, 
positive serum 
galactomanan assay 
C. krusei and  
C. glabrata in bile 
MIC of AMB (mg/L) no positive culture no positive culture C. krusei 0.25/0.38 
C. glabrata 0.38 
 
AMB formulation 
 
LAMB 
 
LAMB 
 
ABCD 
Dose (mg/d) 250  200  400 (1st dose: 200) 
Dose (mg/kg/d) 2.78  3.77  5.56 (1st dose: 
2.38) 
Day of AMB 1, 7 5 1, 4 
2 
 
Legend to Table 1 
CVVH, continuous veno-venous hemofiltration because of acute renal failure; Creatinine, 
plasma creatinine, normal range 0.70 - 1.20 mg/dL; Bilirubin, total plasma bilirubin, normal 
range 0.00 - 1.28 mg/dL; aPPT, activated partial thromboplastin time, normal range 26 – 37 
sec; PT, prothrombin time, normal range 70 - 130 %; INR, international normalized ratio; 
AST, aspartate-aminotransferase, normal range 10 - 50 U/L; ALT, alanine-aminotransferase, 
normal range 10 - 50 U/L; γGT, gamma glutamyl transferase, normal range 10 - 71 U/L; Alk. 
phos., alkaline phosphatase, normal range 40 – 130 U/L; Albumin, plasma albumin 
concentration, normal range 4.19 – 5.35; plasma albumin concentration was determined up to 
14 days before the study day; Total protein, normal range 6.60 – 8.70; COP, colloid osmotic 
pressure, normal range 19.0 – 30.0 mmHg; St. p. LTX, status post liver transplantation; FLC, 
fatty liver cirrhosis; M. Wilson, Wilson disease (hepatolenticular degeneration); ICH, 
intracranial haemorrhage;; ERCP, endoscopic retrograde cholangiopancreatography; n. a. not 
applicable; IFI, invasive fungal infection; BAL, broncho-alveolar lavage; CT, computerised 
tomography; C., Candida; AMB, amphotericin B; LAMB, liposomal amphotericin B 
(AmBisome®); ABCD, amphotericin B colloidal dispersion (Amphocil®, Amphotec®); n. d., 
not determined 
 
Table 2: Plasma pharmacokinetics of liberated, lipid-bound, and total AMB during treatment with liposomal AMB (LAMB) or AMB colloidal 
dispersion (ABCD) 
  Patient 1 Patient 2 Patient 3 
AMB therapy LAMB LAMB ABCD 
 
Single dose Multiple dose Multiple doses Single dose Multiple doses 
Dose (mg/d) 250 250 200 200 400 
Dose (mg/kg/d) 2.78 2.78 3.77 2.38 5.56 
Day of AMB 1 7 5 1 5 
  LI LB TO LI LB TO LI LB TO LI LB TO LI LB TOT 
Cmax (mg/L) 2.45 4.82 7.25 5.15 9.46 14.60 2.54 6.99 9.53 0.27 0.51 0.78 1.10 0.34 1.45 
Cmin (mg/L) 1.18 0.34 1.52 3.01 1.06 4.07 1.59 1.13 2.72 0.02 0.01 0.03 0.03 0.02 0.05 
AUC0-n 37.53a 28.41a 66.51a 93.19a 87.91a 181.63a 33.18b 58.34b 106.04b 1.65a 1.69a 3.39a 14.09a 3.00a 16.13a 
t1/2 (h) 13.26 6.20 8.29 24.58 7.15 12.01 26.93 3.93 6.40 10.50 9.91 10.04 2.84 5.85 3.34 
CL (ml/h/kg) 50 90 30 10 30 10 40 60 30 1,420 1,520 730 390 1,730 340 
Vd (L/kg) 0.89 0.79 0.40 0.51 0.29 0.20 1.62 0.33 0.31 21.48 21.80 10.55 1.60 14.55 1.63 
 
 
 
 
 
 
Legend to Table 2 
AMB, Amphotericin B; LAMB, liposomal AMB; ABCD, AMB colloidal dispersion; LI, liberated AMB; LB, lipid-bound AMB; TO, total AMB; 
total AMB plasma concentrations were calculated by addition of liberated and lipid-bound concentrations. Thus, a time-total-AMB-concentration 
curve was obtained. The plasma pharmacokinetics of total AMB was calculated from this curve; the first ABCD dose amounted to 50 percent of the 
maintenance dose in order to avoid infusion-related toxicity; Cmax, AMB peak concentration; Cmin AMB minimum concentration; AUC0-n, area 
under the AMB concentration-time curve over the sampling period, from 0 (before AMB infusion) to n (time after start of AMB infusion) a n = 24 h 
or b n = 16 h; t1/2, AMB half-life; CL, AMB clearance; Vd, volume of distribution. 
 
Table 3: In-vitro simulation of Candida growth in porcine bile and in RPMI culture medium 
C. albicans  
  
no 
AMB 
0.025 mg/L 
AMB 
0.05 mg/L 
AMB 
0.5 mg/L 
AMB 
1.0 mg/L 
AMB 
5.0 mg/L 
AMB 
porcine bile ++ ++ ++ ++ ++ +/- 
RPMI pH 7.2 ++ ++ ++ + +/- -- 
RPMI pH 7.8  ++ ++ ++ + + -- 
            
 C. glabrata  
  
no 
AMB 
0.025 mg/L 
AMB 
0.05 mg/L 
AMB 
0.5 mg/L 
AMB 
1.0 mg/L 
AMB 
5.0 mg/L 
AMB 
porcine bile + + + + +/- +/- 
RPMI pH 7.2 ++ ++ ++ ++ +/- -- 
RPMI pH 7.8  ++ ++ ++ ++ -- -- 
            
 C. krusei 
 
  
no 
AMB 
0.025 mg/L 
AMB 
0.05 mg/L 
AMB 
0.5 mg/L 
AMB 
1.0 mg/L 
AMB 
5.0 mg/L 
AMB 
porcine bile +/- +/- +/- +/- +/- +/- 
RPMI pH 7.2 ++ ++ ++ ++ ++ -- 
RPMI pH 7.8  ++ ++ ++ ++ +/- -- 
            
 C. tropicalis  
  
no 
AMB 
0.025 mg/L 
AMB 
0.05 mg/L 
AMB 
0.5 mg/L 
AMB 
1.0 mg/L 
AMB 
5.0 mg/L 
AMB 
porcine bile ++ + + + ++ +/- 
RPMI pH 7.2 ++ + ++ + - -- 
RPMI pH 7.8  ++ ++ ++ + +/- -- 
 
Legend to Table 3: 
Candida strains were incubated in amphotericin B-spiked porcine bile and RPMI medium, 
respectively, for up to 48 h (see 2.3 in the text). Amphotericin B deoxycholate was added at 
concentrations of 0.0 (control), 0.025, 0.05, 0.5, 1.0 and 5.0 mg/L. C., Candida; AMB, 
amphotericin B deoxycholate; RPMI, RPMI media at pH 7.2 and at pH 7.8 (adjusted to biliary 
pH); CFU, colony-forming units; - = 10-100-fold decrease in CFU; -- = decrease in CFU by a 
factor of 100 or more; +/- = neither fungal growth nor fungal decease; + = 10-100-fold 
increase in CFU; ++ = increase in CFU by a factor of 100 or more;  
 
Table 4: Ex-vivo simulation of candida growth in patient bile samples 
Time from 
infusion (h) 0 (before) 4 6 10 16 24 
Patient 1 
      Day 1 of LAMB        
C. tropicalis +/- no sample no sample +/- +/- +/- 
AMB (mg/L) <LLOQ - - 0.23 0.16 0.42 
Day 7 of LAMB       
C. albicans no sample +/- +/- +/- +/- +/- 
AMB (mg/L) - 0.92 1.21 1.02 1.28 0.88 
       Patient 2 
      Day 5 of LAMB       
C. albicans no sample + + + +/- no sample 
AMB (mg/L) - 0.09 0.40 0.33 0.02 - 
       Patient 3 
      Day 1 of ABCD       
C. krusei no sample + +/- +/- +/- +/- 
C. glabrata no sample ++ +/- +/- +/- +/- 
AMB (mg/L) - <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ 
Day 4 of ABCD        
C. krusei + + + + ++ +/- 
C. glabrata +/- +/- +/- +/- + +/- 
AMB (mg/L) 0.02 0.03 0.02 0.03 0.04 0.02 
 
 
Legend to Table 4: 
Patient bile samples retrieved during treatment with liposomal amphotericin B or 
amphotericin B colloidal dispersion were incubated with Candida (104 conidia) for a 
maximum of 48 h (see 2.3 in the text). 
Time from infusion, time after start of infusion of LAMB and ABCD, respectively, the 
infusion time amounted to 4 h; LAMB, liposomal amphotericin B (AmBisome®); ABCD, 
amphotericin B colloidal dispersion (Amphocil®, Amphotec®); AMB, amphotericin B; +/- = 
neither fungal growth nor fungal eradication; + = 10-100-fold increase in CFU; ++ = increase 
in CFU by a factor of 100 or more; LLOQ, lower limit of quantification (< 0.025 mg/L); C., 
Candida 
